Literature DB >> 24326266

Enhancement of SIV-specific cell mediated immune responses by co-administration of soluble PD-1 and Tim-3 as molecular adjuvants in mice.

Lijun Xiao1, Dimin Wang, Caijun Sun, Pingchao Li, Yi Jin, Liqiang Feng, Ling Chen.   

Abstract

The development of an effective T cell based HIV vaccine would need to elicit cell mediated immune responses with superior magnitude, breadth, and quality. Since blocking the interactions between inhibitory receptors with their associated ligands using soluble PD-1 (sPD-1) and soluble Tim-3 (sTim-3) have been shown to reverse T cell exhaustion and enhance cell mediated immune responses, we tested if co-administration of sPD-1 and sTim-3 with an adenovirus vectored SIV vaccine (rAd5-SIV) can enhance cell mediated immune responses. The frequency of SIV antigen specific IFN-γ spot-forming cells and the secretion of IFN-γ and TNF-α by splenocytes from rAd5-SIV immunized mice was significantly increased when stimulated ex vivo with SIV peptides in the presence of sPD-1 or sTim-3 or both sPD-1 and sTim-3. The magnitude of cell mediated immune responses elicited by rAd5-SIV was enhanced by co-administration of sPD-1 and sTim-3. Co-administration of both sPD-1 and sTim-3 induced higher frequency of SIV antigen specific IFN-γ(+) spot-forming cells to poorly immunogenic Vif and Tat. The percentage of cell mediated responses for each SIV antigen became more balanced, with reduction to Gag but induction to non-structural proteins. Furthermore, co-injection of rAd5-sPD1 and rAd5-sTim3 with rAd5-SIV in mice enhanced T cell proliferation capability and generated more antigen specific IFN-γ(+) CD4(+) and CD8(+) T cells. Our study provided a new approach to enhance vaccine induced cell mediated immune responses, which may be applicable to improve the efficacy of vaccines against SIV/HIV.

Entities:  

Keywords:  SIV; adjuvant; immunogenicity; soluble PD-1; soluble Tim-3

Mesh:

Substances:

Year:  2013        PMID: 24326266      PMCID: PMC4130272          DOI: 10.4161/hv.27340

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  46 in total

Review 1.  HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation.

Authors:  M L del Rio; C L Lucas; L Buhler; G Rayat; J I Rodriguez-Barbosa
Journal:  J Leukoc Biol       Date:  2009-12-09       Impact factor: 4.962

2.  HCV-specific T cells in HCV/HIV co-infection show elevated frequencies of dual Tim-3/PD-1 expression that correlate with liver disease progression.

Authors:  Bahareh Vali; R Brad Jones; Ali Sakhdari; Prameet M Sheth; Kiera Clayton; Feng-Yun Yue; Gabor Gyenes; David Wong; Marina B Klein; Sahar Saeed; Erika Benko; Colin Kovacs; Rupert Kaul; Mario A Ostrowski
Journal:  Eur J Immunol       Date:  2010-09       Impact factor: 5.532

3.  Enhancement of Gag-specific but reduction of Env- and Pol-specific CD8+ T cell responses by simian immunodeficiency virus nonstructural proteins in mice.

Authors:  Yinfeng Zhang; Caijun Sun; Liqiang Feng; Lijun Xiao; Ling Chen
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-14       Impact factor: 2.205

4.  Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins.

Authors:  B E Johansson; T M Moran; E D Kilbourne
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection.

Authors:  Arlene H Sharpe; E John Wherry; Rafi Ahmed; Gordon J Freeman
Journal:  Nat Immunol       Date:  2007-03       Impact factor: 25.606

6.  Blockade of programmed death ligand 1 enhances the therapeutic efficacy of combination immunotherapy against melanoma.

Authors:  Shari Pilon-Thomas; Amy Mackay; Nasreen Vohra; James J Mulé
Journal:  J Immunol       Date:  2010-03-01       Impact factor: 5.422

7.  Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9.

Authors:  Michelle K Gleason; Todd R Lenvik; Valarie McCullar; Martin Felices; M Shea O'Brien; Sarah A Cooley; Michael R Verneris; Frank Cichocki; Carol J Holman; Angela Panoskaltsis-Mortari; Toshiro Niki; Mitsuomi Hirashima; Bruce R Blazar; Jeffrey S Miller
Journal:  Blood       Date:  2012-02-08       Impact factor: 22.113

8.  Negative immune regulator Tim-3 is overexpressed on T cells in hepatitis C virus infection and its blockade rescues dysfunctional CD4+ and CD8+ T cells.

Authors:  Lucy Golden-Mason; Brent E Palmer; Nasim Kassam; Lisa Townshend-Bulson; Stephen Livingston; Brian J McMahon; Nicole Castelblanco; Vijay Kuchroo; David R Gretch; Hugo R Rosen
Journal:  J Virol       Date:  2009-07-08       Impact factor: 5.103

9.  Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection.

Authors:  Nattawat Onlamoon; Kenneth Rogers; Ann E Mayne; Kovit Pattanapanyasat; Kazuyasu Mori; Francois Villinger; Aftab A Ansari
Journal:  Immunology       Date:  2008-02-05       Impact factor: 7.397

10.  Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.

Authors:  Caijun Sun; Liqiang Feng; Yinfeng Zhang; Lijun Xiao; Weiqi Pan; Chufang Li; Linqi Zhang; Ling Chen
Journal:  J Virol       Date:  2012-08-01       Impact factor: 5.103

View more
  7 in total

Review 1.  HIV-specific CD8⁺ T cells and HIV eradication.

Authors:  R Brad Jones; Bruce D Walker
Journal:  J Clin Invest       Date:  2016-01-05       Impact factor: 14.808

2.  Prokaryotic expression of the extracellular domain of porcine programmed death 1 (PD-1) and its ligand PD-L1 and identification of the binding with peripheral blood mononuclear cells in vitro.

Authors:  Yan-Ping Zhu; Feng Yue; Yong He; Peng Li; Yuan Yang; Yu-Ting Han; Yan-Fang Zhang; Guo-Peng Sun; Dong-Guang Guo; Mei Yin; Xuan-Nian Wang
Journal:  Can J Vet Res       Date:  2017-04       Impact factor: 1.310

3.  Soluble TIM3 and Its Ligands Galectin-9 and CEACAM1 Are in Disequilibrium During Alcohol-Related Liver Disease and Promote Impairment of Anti-bacterial Immunity.

Authors:  Antonio Riva; Elena Palma; Dhruti Devshi; Douglas Corrigall; Huyen Adams; Nigel Heaton; Krishna Menon; Melissa Preziosi; Ane Zamalloa; Rosa Miquel; Jennifer M Ryan; Gavin Wright; Sarah Fairclough; Alexander Evans; Debbie Shawcross; Robert Schierwagen; Sabine Klein; Frank E Uschner; Michael Praktiknjo; Krum Katzarov; Tanya Hadzhiolova; Slava Pavlova; Marieta Simonova; Jonel Trebicka; Roger Williams; Shilpa Chokshi
Journal:  Front Physiol       Date:  2021-03-10       Impact factor: 4.566

4.  Soluble programmed cell death receptor-1 (sPD-1): a potential biomarker with anti-inflammatory properties in human and experimental acute respiratory distress syndrome (ARDS).

Authors:  Sean F Monaghan; Chun-Shiang Chung; Yaping Chen; Joanne Lomas-Neira; William G Fairbrother; Daithi S Heffernan; William G Cioffi; Alfred Ayala
Journal:  J Transl Med       Date:  2016-11-11       Impact factor: 5.531

5.  An adenovirus serotype 2-vectored ebolavirus vaccine generates robust antibody and cell-mediated immune responses in mice and rhesus macaques.

Authors:  Yupeng Feng; Chufang Li; Peiyu Hu; Qian Wang; Xuehua Zheng; Yongkun Zhao; Yi Shi; Songtao Yang; Changhua Yi; Ying Feng; Chunxiu Wu; Linbing Qu; Wei Xu; Yao Li; Caijun Sun; Fu Geroge Gao; Xianzhu Xia; Liqiang Feng; Ling Chen
Journal:  Emerg Microbes Infect       Date:  2018-06-06       Impact factor: 7.163

6.  Soluble Tim3 detection by time-resolved fluorescence immunoassay and its application in membranous nephropathy.

Authors:  Ming Chen; Liang Wang; Yigang Wang; Xiumei Zhou; Xinyuan Liu; Hao Chen; Biao Huang; Zhigang Hu
Journal:  J Clin Lab Anal       Date:  2020-02-20       Impact factor: 2.352

7.  Highly elevated soluble Tim-3 levels correlate with increased hepatocellular carcinoma risk and poor survival of hepatocellular carcinoma patients in chronic hepatitis B virus infection.

Authors:  Fang Li; Na Li; Jiao Sang; Xiude Fan; Huan Deng; Xiaoge Zhang; Qunying Han; Yi Lv; Zhengwen Liu
Journal:  Cancer Manag Res       Date:  2018-05-01       Impact factor: 3.989

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.